Among patents that demonstrated HER2 overexpression, 41 of them were enrolled to evaluate the clinical value of single-agent trastuzumab in recurrent ovarian cancer, and an overall response rate of 7.3% was observed [111]. Here, ERBB2 is linked to ovarian carcinoma.